Palisade Bio Appoints Dr. Jonathan T. Hunt as CEO
Ticker: PALI · Form: 8-K · Filed: Mar 6, 2024 · CIK: 1357459
| Field | Detail |
|---|---|
| Company | Palisade Bio, Inc. (PALI) |
| Form Type | 8-K |
| Filed Date | Mar 6, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, ceo-appointment
TL;DR
Palisade Bio names Dr. Jonathan T. Hunt as new CEO, effective Feb 29.
AI Summary
Palisade Bio, Inc. announced on March 6, 2024, that its Board of Directors appointed Dr. Jonathan T. Hunt as Chief Executive Officer, effective February 29, 2024. Dr. Hunt will also serve as a member of the Board. He previously held the position of Chief Medical Officer at the company.
Why It Matters
The appointment of a new CEO can signal a strategic shift or a renewed focus for the company, potentially impacting its future development and stock performance.
Risk Assessment
Risk Level: medium — CEO changes can introduce uncertainty regarding future strategy and execution, impacting investor confidence.
Key Players & Entities
- Palisade Bio, Inc. (company) — Registrant
- Dr. Jonathan T. Hunt (person) — Appointed CEO
- February 29, 2024 (date) — Effective date of appointment
- March 6, 2024 (date) — Date of report
FAQ
Who has been appointed as the new Chief Executive Officer of Palisade Bio, Inc.?
Dr. Jonathan T. Hunt has been appointed as the new Chief Executive Officer of Palisade Bio, Inc.
When did the appointment of Dr. Jonathan T. Hunt as CEO become effective?
The appointment of Dr. Jonathan T. Hunt as CEO became effective on February 29, 2024.
What was Dr. Jonathan T. Hunt's previous role at Palisade Bio, Inc.?
Dr. Jonathan T. Hunt's previous role at Palisade Bio, Inc. was Chief Medical Officer.
Will Dr. Jonathan T. Hunt also serve on the Board of Directors?
Yes, Dr. Jonathan T. Hunt will also serve as a member of the Board of Directors.
What is the filing date of this 8-K report?
The filing date of this 8-K report is March 6, 2024.
Filing Stats: 642 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2024-03-06 16:35:16
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share PALI Nasdaq Capital Marke
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex3-1.htm (EX-3.1) — 233KB
- 0001493152-24-009042.txt ( ) — 482KB
- pali-20240306.xsd (EX-101.SCH) — 3KB
- pali-20240306_lab.xml (EX-101.LAB) — 33KB
- pali-20240306_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 6, 2024 Palisade Bio, Inc. /s/ J.D. Finley By: J.D. Finley Chief Executive Officer